Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

N/A

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 2(3)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01928576Phase 2Completed

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Role: collaborator

NCT00005096Phase 2Completed

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

Role: collaborator

NCT00148070Phase 2Completed

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Role: collaborator

NCT00321009Not ApplicableCompleted

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin

Role: collaborator

NCT00000980Phase 1Completed

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

Role: lead

NCT00002062Not ApplicableCompleted

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

Role: lead

All 6 trials loaded